ScinoPharm to manufacture topiramate for Qsymia
ScinoPharm Taiwan's Taiwan facility is to provide commercial manufacturing of topiramate active pharmaceutical ingredient (API) for Vivus' Qsymia, a new drug for the treatment of obesity recently approved by the FDA.
Qsymia is an FDA-approved once-daily combination treatment for chronic weight management in adults who are obese or overweight with a weight-related comorbidity. It is a combination of an anticonvulsant, topiramate and appetite suppressant, phentermine. Topiramate is an API that ScinoPharm began commercial production of two years ago for the treatment of epilepsy and other nervous system disorders as a generic API.
ScinoPharm is currently expanding its manufacturing and process development capabilities through its new mainland China facility in Changshu, which will initially be used for the production of pharmaceutical intermediates with CGMP-grade API production planned for the near future.